Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

AIMS: To evaluate the dose–response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes. METHODS: Randomized, double-blind, placebo-controlled, parallel-group, 13 week study of 542 patients with Type 2 diabete...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratner, R E, Rosenstock, J, Boka, G
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068287/
https://www.ncbi.nlm.nih.gov/pubmed/20722676
http://dx.doi.org/10.1111/j.1464-5491.2010.03020.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068287/
https://www.ncbi.nlm.nih.gov/pubmed/20722676
http://dx.doi.org/10.1111/j.1464-5491.2010.03020.x

Ejemplares similares